Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience
Krishan R. Jethwa(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Harigopal Sandhyavenu(Mayo Clinic), David M. Routman(Mayo Clinic in Arizona), William S. Harmsen(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Courtney N. Day(Mayo Clinic), M.A. Neben-Wittich(Mayo Clinic), Karthik Gonuguntla(Mayo Clinic in Arizona), William G. Breen(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Allison E. Garda(Mayo Clinic in Arizona), Þorvarður R. Hálfdánarson(Mayo Clinic), Joleen M. Hubbard(Rutgers, The State University of New Jersey)
Cited by 8
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
|Endocrine Related Cancer|2008|374